Shares of healthcare company Baxter International (NYSE:BAX)
fell 2.9% in the afternoon session after the stock continued to fall as the company reported mixed third-quarter results, lowered its full-year guidance, and announced a plan to reduce its dividend. While adjusted earnings per share of $0.69 beat expectations, revenue of $2.84 billion fell short of forecasts. The positive earnings were overshadowed by several concerns. The company's gross margin plunged due to product mix shifts and higher manufacturing costs. Baxter also lowered its 2025 adjusted earnings outlook to a range of $2.35 to $2.40 and trimmed its full-year sales growth target. Adding to the issues, the company faced ongoing operational problems, including a shipment hold for its Novum IQ Large Volume Pump. Finally, Baxter said it would slash its quarterly dividend starting in January 2026 to free up cash to pay down debt.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 13.5% in the morning session after the company reported disappointing third-quarter financial results, which included a miss on revenue and a weak outlook.
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.
Baxter (BAX) Q3 2025 earnings beat EPS estimates but revenue missed forecasts. The stock fell sharply on the revenue miss and a cautious Q4 sales outlook.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 3% in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 13.9% return has trailed the S&P 500 by 18.8 percentage points.
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 3.7% in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Baxter has gotten torched over the last six months - since March 2025, its stock price has dropped 32% to $22.86 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
